Lupin Ltd News

Lupin slips 9%, hits 2-year low on disappointing March quarter results_64297

Lupin's performance was skewed on revenues front amid US and India posting lower than expected sales while RoW and South Africa saw better than anticipated traction this quarter.

Lupin receives USFDA approval for anti-depressant drug_53638

It is the generic equivalent of Pristiq, extended-release tablets, 25 mg of PF PRISM C.V, it added

Lupin's New Jersey facility gets 13 US FDA observations_49398

The observations do not, however, imply any restriction on supplies

Lupin slips 9% in two days, hits 52-week low on disappointing Q3 results_28383

In the past six months, the stock has shed nearly 30 per cent, as compared to a 7 per cent rise in the S&P BSE Sensex.

Lupin slips 5%, nears 52-week low post December quarter results_27554

The company reported lower-than-expected margins and net profit in December quarter due to one-time expenses related to residual metformin returns and provision for aged stock returns of Oseltamivir.

Pharma shares trade firm; Laurus up 2%, Sun Pharma nears 52-week high_12610

Sun Pharma, Cipla, Natco, Dr Reddy's, Torrent Pharma, Aurobindo Pharma and Strides have launched a generic version of Molnupiravir in India post approval for emergency use authorisation from DCGI

Stocks to Watch: HP Adhesives, RBL Bank, Adani Trans, HUL, Lupin, CBI_11682

HP Adhesives is likely to debut with a 20-25 per cent listing gain, as per indications from the GMP

US business rebound key to further upsides in Lupin, VAI may offer relief_7866

Clearance for Goa unit is positive; near-term triggers are new launches and market share gains

US FDA clears Lupin's Goa plant, paves way for new product approvals_6980

Goa plant has an annual capacity of 6 billion units of tablets, capsules or oral suspension drugs. It accounts for 18-20% of firm's US revenue

Lupin surges 10% on good volumes after getting EIR from USFDA for Goa plant_6724

Despite of today's gain, the stock has underperformed the market by falling 18 per cent in past six months, as compared to 10.5 per cent rally in the S&P BSE Sensex

Lupin to set up 100 diagnostic labs and 1,000 collection centres in 5 yrs_5784

Announced foray into fragmented diagnostic business where organised chains have less than 20% share of overall business

BSE Healthcare index up 2%; Cipla, Alkem, Dr.Reddy's rally up to 8%_210

The pharma index had taken a breather over the past three months after displaying relative out-performance during CY20-21.